Skip to main content

and
Your search also matched 4 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you.
results, e.g.

Imatinib and beyond—exploring the full potential of targeted therapy for CML

Include preview-only content
  1. Article

    Open Access

    Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

    Talacotuzumab, a humanized anti-CD123 monoclonal antibody, was evaluated in combination with decitabine in elderly patients with acute myeloid leukemia (AML) not eligible for intensive chemotherapy. A multicen...

    Pau Montesinos, Gail J. Roboz, Claude-Eric Bulabois, Marion Subklewe in Leukemia (2021)

  2. Article

    Open Access

    Predictive models for health outcomes due to SARS-CoV-2, including the effect of vaccination: a systematic review

    The interaction between modelers and policymakers is becoming more common due to the increase in computing speed seen in recent decades. The recent pandemic caused by the SARS-CoV-2 virus was no exception. Thu...

    Oscar Espinosa, Laura Mora, Cristian Sanabria, Antonio Ramos in Systematic Reviews (2024)

  3. Article

    Open Access

    Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials

    Ponatinib, the only approved all known-BCR::ABL1 inhibitor, is a third-generation tyrosine-kinase inhibitor (TKI) designed to inhibit BCR::ABL1 with or without any single resistance mutation, including T315I, ...

    Elias Jabbour, Jane Apperley, Jorge Cortes, Delphine Rea, Michael Deininger in Leukemia (2024)